Gadoquatrane
As of the edition of 20 October 2026, Gadoquatrane is a small molecule: marketed, first approved in 2026 (US); US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Ambelvist
- First approved
- 12 June 2026 (US)
- Approvals on record
- 10 in 3 regions
- Holder of the most recent approval
- Bayer; 2 holders in all
- Registered trials
- 7, 0 stopped early
US protection
US protection ends in 2036.
The last listed US drug-substance patent ends in 2036. The application that gives this date is held by Bayer.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product30 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 30 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Originator, Applicant and Lead sponsor of trials | 2019 to now |